Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is an heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, molecular diagnosis, heart repair and advanced therapies. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

216

total

1,044.403

impact factor

4.853

average impact factor

Director: Rafael Parra López

team

We are dedicated to investigate transfusional activity, the alteration of red blood cells during the conservation period and the usefulness of extracorporeal photoapheresis. We work on the molecular and serological characterization of blood group variants. In non-invasive fetal genotyping strategies due to blood group incompatibilities. We develop iPSC lines and produce in vitro red blood cells with rare erythrocytic phenotypes.

We deepen in the knowledge of the epidemiology and the detection of infectious agents relevant for the safety of the products supplied by the Blood and Tissue Bank.

We investigate in clinical immunology and develop our own HLA and KIR typing protocols. We develop and incorporate new therapeutic applications in the area of ??cell therapy including hematopoietic transplantation, cellular immunology and regenerative medicine.

We investigate the molecular mechanisms and the genotype-phenotype correlation of coagulopathies, hemorrhagic diathesis and other associated congenital pathologies. We develop tools based on the new technologies of parallel massive sequencing with application to the molecular study, genetic counselling and prenatal diagnosis.

18

total

100^.173

impact factor

5^.565

average impact factor

SELECTED ARTICLES

Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Comprehensive genetic analysis by next-generation sequencing of 480 patients.
Haematologica. 2017 Dec;102(12):2005-2014.doi:10.3324/haematol.2017.168765. Epub 2017 Sep 29
PMID: 28971901
IF: 7,702
Authors: Borràs N, Batlle J, Pérez-Rodríguez A, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruín G, Herrero S, Soto I, de Rueda B, Jimimenez-Yuste V, Alonso N, Vilariño D, Arija O, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Sarmiento L, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, César JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Vidal F, Corrales I.
DOI: 10.3324/haematol.2017.168765

Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series.
Haemophilia. 2017 Mar;23(2):255-263. doi: 10.1111/hae.13167. Epub 2017 Feb 15
PMID: 28205285
IF:2,673
Authors: Iorio A, Barbara AM, Makris M, Fischer K, Castaman G, Catarino C, Gilman E, Kavakli K, Lambert T, Lassila R, Lissitchkov T, Mauser-Bunschoten E, Mingot-Castellano ME, Ozdemir N, Pabinger I, Parra R, Pasi J, Peerlinck K, Rauch A, Roussel-Robert V, Serban M, Tagliaferri A, Windyga J, Zanon E
DOI: 10.1111/hae.13167

Advanced cell-based modeling of the royal disease: characterization of the mutated F9 mRNA
J Thromb Haemost. 2017 Nov;15(11):2188-2197. doi: 10.1111/jth.13808. Epub 2017 Sep 25.
PMID: 28834196
IF: 5,097
Authors: Martorell L, Luce E, Vazquez JL, Richaud-Patin Y, Jimenez-Delgado S, Corrales I, Borras N, Casacuberta-Serra S, Weber A, Parra R, Altisent C, Follenzi A, Dubart-Kupperschmitt A, Raya A, Vidal F, Barquinero J
DOI: 10.1111/jth.13808

Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
J Clin Oncol. 2017 Oct 20;35(30):3425-3432. doi: 10.1200/JCO.2017.72.6869. Epub 2017 Aug 28.
PMID: 28846465
IF: 3,212
Authors: Martínez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, Castagna L, Afanasyev B, Robinson S, Blaise D, Corradini P, Itälä-Remes M, Bermúdez A, Forcade E, Russo D, Potter M, McQuaker G, Yakoub-Agha I, Scheid C, Bloor A, Montoto S, Dreger P, Sureda A; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
DOI: 10.1200/JCO.2017.72.6869

Evaluation of the sensitivity and specificity performance of the Elecsys® HTLV-I/II assay in a multicenter study in Europe and Japan
J Clin Microbiol. 2017 Jul;55(7):2180-2187. doi: 10.1128/JCM.00169-17. Epub 2017 May 3.
PMID: 28468860
IF: 3,631
Authors: Laperche S, Sauleda S, Piron M, Mühlbacher A, Schennach H, Schottstedt V, Queirós L, Uno N, Yanagihara K, Imdahl R, Hey A, Klinkicht M, Melchior W, Muench P, Watanabe T.
DOI: 10.1128/JCM.00169-17

View all publications

Immunomediated Diseases and Innovative Therapies

Overview

Publications

Director: Rafael Parra López

Research Areas